Use of platelet‐rich plasma for COVID‐19–related olfactory loss: a randomized controlled trial

CH Yan, SS Jang, HFC Lin, Y Ma… - … Forum of Allergy & …, 2023‏ - Wiley Online Library
Introduction The current study evaluated the use of platelet‐rich plasma (PRP), an
autologous blood product with supraphysiologic concentrations of growth factors, in the …

The assessment of qualitative olfactory dysfunction in COVID-19 patients: a systematic review of tools and their content validity

A Espetvedt, S Wiig, KV Myrnes-Hansen… - Frontiers in …, 2023‏ - frontiersin.org
Background There is a lack of overview of the tools used to assess qualitative olfactory
dysfunction, including parosmia and phantosmia, following COVID-19 illness. This could …

Long-term olfactory loss post-COVID-19: Pathobiology and potential therapeutic strategies

S Kim, JB Finlay, T Ko, BJ Goldstein - World Journal of …, 2024‏ - mednexus.org
An acute loss of smell emerged as a striking symptom present in roughly half of the people
infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in …

Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter …

A Di Stadio, S Gallina, S Cocuzza, P De Luca… - European Archives of …, 2023‏ - Springer
Purpose Few evidence-based therapies are available for chronic olfactory dysfunction after
COVID-19. This study investigated the relative efficacy of olfactory training alone, co …

Development and psychometric validation of the olfactory dysfunction outcomes rating

JJ Lee, A Mahadev, D Kallogjeri… - … –Head & Neck …, 2022‏ - jamanetwork.com
Importance Olfactory dysfunction (OD) is an increasingly common and morbid condition,
especially given the ongoing COVID-19 pandemic. Thus, the ability to reproducibly measure …

A systematic review of the role of purinergic signalling pathway in the treatment of COVID-19

VG Korb, IC Schultz, LR Beckenkamp… - International Journal of …, 2023‏ - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has become a global health concern. Three years …

Post-COVID-19 anosmia and therapies: Stay tuned for new drugs to sniff out

G Riccardi, GF Niccolini, MG Bellizzi, M Fiore, A Minni… - Diseases, 2023‏ - mdpi.com
Background: Anosmia is defined as the complete absence of olfactory function, which can
be caused by a variety of causes, with upper respiratory tract infections being among the …

Evaluation of novel nasal mucoadhesive nanoformulations containing lipid-soluble EGCG for long COVID treatment

N Frank, D Dickinson, G Lovett, Y Liu, H Yu, J Cai… - Pharmaceutics, 2024‏ - mdpi.com
Following recovery from the acute infection stage of the SARS-CoV-2 virus (COVID-19),
survivors can experience a wide range of persistent Post-Acute Sequelae of COVID-19 …

[HTML][HTML] Delivery of topical drugs to the olfactory cleft

A Espehana, L Lee, EM Garden, G Klyvyte… - Journal of Clinical …, 2023‏ - mdpi.com
Olfactory dysfunction affects approximately 20% of the population globally, with incidence
increasing over the age of 60. The pathophysiology is complex, not yet fully understood, and …

A comprehensive review of COVID-19-related olfactory deficiency: unraveling associations with neurocognitive disorders and magnetic resonance imaging findings

L Simonini, F Frijia, L Ait Ali, I Foffa, C Vecoli, C De Gori… - Diagnostics, 2024‏ - mdpi.com
Olfactory dysfunction (OD) is one of the most common symptoms in COVID-19 patients and
can impact patients' lives significantly. The aim of this review was to investigate the …